1. |
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group[J]. N Engl J Med, 1997, 337(15): 1029-1035.
|
2. |
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial[J]. Lancet, 2002, 359(9317): 1541-1549.
|
3. |
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis[J]. New Engl J Med , 2005, 353(23): 2462-2476.
|
4. |
孙怡燕, 吴永发, 徐灿, 等. 英夫利西单抗治疗克罗恩病的疗效观察[J]. 第二军医大学学报, 2010, 31(3): 338-339.
|
5. |
Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort[J]. Gut, 2009, 58(4): 492-500.
|
6. |
Kraemer M, Kirschmeier A, Marth T. Perioperative adjuvant therapy with infliximab in complicated anal Crohn’s disease[J]. Int J Colorectal Dis, 2008, 23(10): 965-969.
|
7. |
De Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn’s disease: long-term follow-up of an unselected cohort[J]. Inflamm Bowel Dis, 2008, 14(3): 353-358.
|
8. |
马东梅, 张春燕. 56例类风湿关节炎病人输注类克药物的观察和护理[J]. 护理研究, 2009, 23(20): 1837-1838.
|
9. |
冯楠, 戈之铮. 英夫利昔单抗在炎症性肠病治疗中的应用[J]. 国际消化病杂志, 2008, 28(4): 273-276.
|
10. |
Arhur B, Miguel R. Biologic therapy in the management of extraint estinal manifestations of inflammatory bowel disease[J]. Inf lam m Bow el Dis, 2007, 13: 1424-1429.
|
11. |
翁雪玲, 张海嫦, 陈燕. 临床输注英夫利西单抗不良反应的预防及护理[J].解放军护理杂志, 2011, 28(1B): 57-58.
|